Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests best combo to prevent miscarriage

NCT ID NCT07608133

Disease control Sponsor: Pakistan Air Force (PAF) Hospital Islamabad Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 100 women with threatened miscarriage (bleeding and pain in early pregnancy) to see if adding HCG injections to standard dydrogesterone pills works better than pills alone. Both groups took dydrogesterone twice daily; one group also received weekly HCG shots up to 14 weeks. The main goal was to stop bleeding and reduce pain after 14 days. Results will help doctors choose the best treatment to save the pregnancy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Dec 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women with singleton pregnancy diagnosed as threatened miscarriage in the first trimester * Age 18 to 40 years * Presence of vaginal bleeding with or without abdominal pain and closed cervical os * Viable pregnancy confirmed on ultrasound (fetal cardiac activity present) * Willing to provide written informed consent Exclusion Criteria: * History of oxytocin or prostaglandin use during current pregnancy * History of abdominal trauma during pregnancy * Septic abortion or signs of infection * Hemodynamically unstable patients * Known bleeding disorders * Known uterine anomalies * Failed or inevitable miscarriage at presentation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early pregnancy bleeding are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Abortion, Threatened

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early pregnancy bleeding Threatened miscarriage

Contacts and locations

Locations

  • Pakistan Air Force Hospital, Islamabad

    Islamabad, Punjab Province, 44000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.